Regeneron Pharmaceuticals, Inc. will present new clinical data from its oncology pipeline at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain from October 20-24.
The data spotlights the effectiveness of Libtayo® (cemiplimab) as a stand-alone treatment and in combination therapies for various tumors.
Israel Lowy, Senior VP at Regeneron, emphasized their expertise in cancer biology and the immune system, aiming to address high-demand cancer types.
Noteworthy presentations include survival data for Libtayo in cutaneous squamous cell carcinoma and results when combined with ubamatamab in recurrent ovarian cancer.
This progress is further accentuated by the FDA’s recent Fast Track Designation for combining fianlimab (LAG-3) and Libtayo in melanoma treatment.
A highlight from the ESMO presentations will be the one-year survival outcomes from a Phase 2 trial of Libtayo in neoadjuvant CSCC, first shared in the previous ESMO meeting.
Also, Regeneron will introduce Phase 1 results for a Libtayo and ubamatamab combination in treating recurrent ovarian cancer.
Ubamatamab aims to bridge cancer cells and T cells to enhance local T-cell activation.
Further ESMO presentations will explore Libtayo’s role in advanced non-small cell lung cancer, especially focusing on squamous cell carcinoma and PD-L1 expression variations.
It’s important to note that Libtayo’s potential uses and its combinations with other drugs like ubamatamab and BNT116 are still under investigation and await full evaluation for safety and efficacy.
Regeneron’s mission in cancer treatment is to convert groundbreaking discoveries into transformative medicines.
With a foundation in scientific innovation and deep knowledge in biology and genetics, Regeneron is researching therapies for over 30 types of tumors and blood cancers.
Their cancer strategy leverages advanced technologies and treatments for potentially groundbreaking patient solutions.
Almost half of Regeneron’s pipeline consists of oncology assets, including checkpoint inhibitors, bispecific antibodies, and costimulatory bispecific antibodies.
Their approved PD-1 inhibitor, Libtayo, is central to many of their experimental combinations.